U.S. Markets closed
  • S&P 500

    3,635.41
    +57.82 (+1.62%)
     
  • Dow 30

    30,046.24
    +454.97 (+1.54%)
     
  • Nasdaq

    12,036.79
    +156.15 (+1.31%)
     
  • Russell 2000

    1,853.53
    +35.23 (+1.94%)
     
  • Crude Oil

    44.83
    +1.77 (+4.11%)
     
  • Gold

    1,805.20
    -32.60 (-1.77%)
     
  • Silver

    23.27
    -0.36 (-1.54%)
     
  • EUR/USD

    1.1901
    +0.0055 (+0.4641%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3359
    +0.0036 (+0.2739%)
     
  • USD/JPY

    104.4400
    -0.0480 (-0.0459%)
     
  • BTC-USD

    18,864.96
    +412.99 (+2.24%)
     
  • CMC Crypto 200

    374.13
    +4.37 (+1.18%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions

Shanthi Rexaline

Biotech stocks have been buoyant in recent sessions, as reflected by the iShares NASDAQ Biotechnology Index (NASDAQ: IBB), which traded higher for the fourth straight week. The year-end rally that's powering the broader market upside is partly responsible for the upside.

As the year tapers to the close, a look back shows a decent number of new molecule entity approvals and record M&A activity. Big pharma stocks continue to trade at or near the year's highs.

In the upcoming year, stock selection will play a pivotal role, as fears surrounding drug pricing and elections wane, Morgan Stanley said in a recent note.

PDUFA Dates

The FDA is set to rule on Correvio Pharma Corp's (NASDAQ: CORV) NDA for Brinavess, or vernakalant HCl in intravenous formulation, an antiarrhythmic drug that's being evaluated for the rapid onset atrial fibrillation to sinus rhythm for non-surgery patients.

The PDUFA action date is planned for Tuesday. A FDA panel, which met Dec. 10, voted against approval of the drug.

Intra-Cellular Therapies Inc (NASDAQ: ITCI) awaits FDA verdict on its schizophrenia drug Lumateperone, with the decision expected Friday.

Several catalysts, including clinical readouts and NDA/BLA filings, with the timeframe of fourth quarter/December could play out over the next week.

Related Links:

Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial

8 Biotech Stocks Morgan Stanley Recommends For 2020

0

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.